Mealey's (May 19, 2022, 8:56 AM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on May 16 declined to review lower court decisions excluding an expert opinion that the maker of the antidepressant Abilify failed to update the drug label to warn of the risk of the neurological disorder tardive dyskinesia....